The company reported $261 million in revenue and adjusted earnings of $0.09 per share, slightly above analysts' consensus ...

For the quarter, Confluent's overall revenue leaped 23% higher year over year to top $262 million, although its non-GAAP ...

Needham raised the firm’s price target on Confluent (CFLT) to $40 from $31 and keeps a Buy rating on the shares after its Q4 earnings beat.

Evercore ISI analyst Chirag Ved maintained a Buy rating on Confluent (CFLT – Research Report) on February 7 and set a price target of $32.00. The company’s shares closed last Friday at $30.02.

With more than 130 sites of care, IncreMedical Therapy Solutions has been a trusted partner to hospitals and health systems across the United States.Now as Confluent Health System Solutions, the ...

This translated to sustained momentum in new logo acquisition and customer expansions." On the profitability front, we note that Confluent achieved a record pro forma operating margin of 6% in the ...

In the last three months, 11 analysts have published ratings on Confluent (NASDAQ:CFLT), offering a diverse range of perspectives from bullish to bearish. The table below offers a condensed view ...

As such, this is a guest post written by Peter Pugh-Jones, in his capacity as director of strategic accounts at Confluent. Understanding how the cadence and throughput of real-time data impacts ...

After a 14% rise since the beginning of 2024, we believe News Corp stock (NASDAQ: NWSA), a global, diversified media and information services company, could see further gains in the longer term.